Medication info
CandeMova Tablet 10/16 mg

CandeMova Tablet 10/16 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3) - 30 tablets/PTP [30 tablets (10 tablets/PTP X 3)]
Approval status
Active

MFDS item code 202008715 · Approved 2020.12.11

Summary

Main use
Treatment of hypertension and heart failure; improvement of hyperlipidemia; suppression of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. 2. Heart failure 3) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of hyperlipidemia; suppression of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • impaired left ventricular function
  • hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • abnormal beta-lipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • high blood pressure
  • low HDL cholesterol levels
  • risk of stroke
  • risk of myocardial infarction
View approved original text

This medication is used for patients who need to take Candesartan Cilexetil and Rosuvastatin simultaneously. Candesartan Cilexetil is primarily used for patients with essential hypertension and those with heart failure with impaired left ventricular function, especially when additional treatment beyond ACE inhibitors is needed or when tolerance is poor. Rosuvastatin is used supplementary when dietary measures are insufficient for patients with hypercholesterolemia and dyslipidemia. Additionally, it helps reduce the risk of stroke, myocardial infarction, and vascular intervention in patients at high risk of cardiovascular disease. The combination of these two components works to control blood pressure and cholesterol, improving cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. 2. Heart failure 3) Children: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication can cause serious harm to the fetus during pregnancy, especially in the second and third trimesters, and should be stopped immediately if pregnancy is confirmed. It is safest for pregnant or nursing women not to use this medication, and women of childbearing potential should use appropriate contraceptive methods. This medication should not be administered to certain patients with specific liver disease, severely reduced kidney function, history of angioedema, or myopathy. Elderly patients and those with compromised liver or kidney function should use this medication with caution, and regular blood tests may be necessary to monitor liver and kidney function. If symptoms such as muscle pain or weakness occur, consult a doctor immediately, and patients at risk of muscle damage should undergo muscle-related tests before taking this medication. There may be interactions when used in conjunction with other antihypertensives or specific lipid-lowering agents, so inform your doctor or pharmacist of any other medications being taken. Caution is advised when driving or operating machinery as dizziness or fatigue may occur. Store out of reach of children and keep in the original container for safety.

Side effects

Headache, nasopharyngitis, localized infections, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, glare, dyspepsia, increased blood glucose, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, urticaria, nausea, dizziness, orthostatic dizziness, chest discomfort, musculoskeletal pain, neck pain, cataract, rash, increased sweating, hematuria, weakness, fever, paresthesia, dyspepsia, gastritis, tachycardia, palpitations, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, drowsiness, dyspnea, thrombocytopenia, jaundice, hepatitis, liver dysfunction, angioedema, rhabdomyolysis, arthralgia, myalgia, low back pain, renal dysfunction, acute kidney injury, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, facial flushing, facial edema, weight gain, thirst, sleep disorders, reduced libido, amnesia, anorexia, increased appetite, tinnitus, dysgeusia, erectile dysfunction, constipation, abdominal pain, pancreatitis, myopathy, myositis, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, thrombocytopenia, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, immune-mediated myopathy, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, memory impairment, amnesia, cognitive impairment, confusion, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. It is recommended to maintain storage temperature between 1 degree to 30 degrees Celsius. Proper storage will help maintain the efficacy and safety of the medication for a longer time.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3) - 30 tablets/PTP [30 tablets (10 tablets/PTP X 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.